恩他卡朋联合复方左旋多巴治疗帕金森病58例疗效及安全性观察

Clinical Efficacy and Safety of Entacapone Combined with Compound Levodopa in Treating Parkinson's Disease

目的探讨恩他卡朋联合复方左旋多巴治疗帕金森病的临床疗效及安全性。方法将116例帕金森病患者随机分为对照组和观察组,各58例。对照组患者常规服用复方左旋多巴,观察组患者加用恩他卡朋。分别于治疗前和治疗8周时行Hoehn and Yahr病程分级评分、统一帕金森病评分量表(UPDRS)第Ⅱ和Ⅲ部分评分、日常生活能力量表(ADL)评分、非运动症状筛查量表(NMSS)评分,观察药品不良反应。结果治疗后,对照组药物起效时间,开、关期时间及异动时间与试验前相比差异不明显(P>0.05);与试验前相比,观察组患者试验后药物起效时间差异不明显(P>0.05),但开期时间明显延长,关期时间及异动时间明显缩短(P<0.05)。两组患者试验前后Hochn and Yahr病程分级评分均无显著性差异(P>0.05);对照组UPDRS第Ⅱ和Ⅲ部分评分、ADL评分、NMSS评分也无明显改善(P>0.05),观察组患者上述指标则较试验前明显下降(P<0.05)。两组不良反应发生率相当(P>0.05)。结论恩他卡朋联合复方左旋多巴治疗帕金森病疗效确切、稳定,使用过程安全,值得临床推广。

Objective To investigate the clinical effect and safety of entacapone combined with compound levodopa in treating Parkinson＇s disease. Methods 116 patients with Parkinson＇s disease were randomly divided into the control group and the observation group,58 cases in each group. The control group was routinely treated by compound levodopa and the observation group was added with enta-capone. The Hoehn and Yahr course classification score,score of Unified Parkinson＇s Disease Rating Scale（UPDRS）part Ⅱand Ⅲ,the activity of daily living（ADL）score,Non-Motor Symptoms Screening Scale（NMSE）score and the adverse reactions were observed before therapy and at 8 weeks of treatment. Results The effect onset time,opening stage time,closing stage time and the abnormal moving time in the control group had no statistically significant difference between before and after treatment（ P 〉 0. 05）;the effect onset time after treatment in the observation group had no significant difference compared with before treatment,but the opening stage time was significantly prolonged,while the closing stage time and the abnormal moving time were obviously shortened（ P 〈 0. 05）. The Hoehn and Yahr course classification score before and after treatment had no statistically significant differences between the two groups（ P 〉 0. 05）;the score of UPDRS part Ⅱ and Ⅲ,ADL score and NMSS score after treatment in the control group had no obvious improvement （ P 〉 0. 05）,but the above indexes after treatment in the observation group were obviously decreased than before treatment（ P 〈 0. 05）. The occurrence rate of adverse reactions in the two groups was equal. Conclusion Entacapone combined with compound levodopa has defi-nite and stable effect in treating Parkinson＇s disease.